2021 CMSC Annual Meeting

Tag: 7752DMT21Poster-Disease-modifying TherapyDaniel Kantor

Poster-Disease-modifying Therapy

Number-Needed-to-Harm (NNH) in Alemtuzumab and Ocrelizumab Pivotal Clinical Trials in Relapsing MS

Background: Alemtuzumab (ALE) and ocrelizumab (OCR) are widely recognized as among the highest efficacy multiple sclerosis (MS) disease...

Read More